Buy DMT

From magic mushrooms to psychedelic toads, a booming trade of wild plants, fungi and animals is taking place on the dark web. An investigation by researchers from Australia’s University of Adelaide has found scores of plant, fungi and animal species being sold for recreational drugs or purported medicinal use. Their research, published in the journal PLOS Biology, trawled 51 dark-web marketplaces to find 153 species being offered for sale. Plants accounted for 58 per cent of the advertised sales, followed by fungi at 39 per cent and animals at 3 per cent. The researchers found the trade was largely unregulated and that many of the vendors were using social media to advertise their products.

“We are amidst a human-driven mass extinction event where the direct harvesting of wildlife constitutes one of the largest threats to biodiversity and species survival,” they wrote in their paper. The research highlights the need for better enforcement of laws to curb the illegal online market for these wild species. “The current state of global drug law enforcement and wildlife conservation is utterly inadequate,” they said.

It’s a powerful hallucinogenic, and it’s not uncommon for users to report otherworldly experiences. Users have reported meeting kaleidoscope-like shapes, being pulled by a strong force to new dimensions and encountering other entities such as “DMT elves” and “machine elves”. The drug has also been linked to feelings of transcendence, spirituality and a greater sense of well-being.

However, despite its psychedelic effects, DMT has relatively low toxicity. The NSW drug information website says it can be extracted naturally from the wattle tree and is commonly used in Australian psychedelic brews such as Ayahuasca. The natural Buy DMT in Australia is believed to be more potent than the synthetic version.

How to Buy DMT in Australia

Medicinal MDMA and psilocybin, the active ingredient in magic mushrooms, have shown promise in treating depression and post-traumatic stress disorder (PTSD) in small clinical trials. However, the Therapeutic Goods Administration will only reschedule them for use in closely controlled clinical trials. This means the drugs will remain prohibited in all other circumstances.

A Melbourne-based company plans to accelerate the process of developing new pharmaceutical-grade psychedelics. The Psychae Institute, a collaboration between scientists from world-leading universities, will launch in Melbourne on Friday. It hopes to develop clinical studies of the drugs’ therapeutic benefits and eventually have them approved as medicines.

Dr Chris Langmead, from Monash University, is involved in a pilot trial at St Vincent’s Hospital where terminally ill cancer patients are invited to confront their deepest fears under the influence of psilocybin. They are provided with psychotherapy before, during and after the psychedelic experience. He believes a large international consortium of psychedelic researchers would be able to get the drugs fast-tracked more quickly than an individual university working on its own.